Trial site
Villejuif
Villejuif, 94805, FranceNot linked to an institution yet
- 13running trials
- 2closed trials
The trials here
What the 15 trials at this site are about, from their registry records.
- Phase
- Phase 1/210 trials
- Phase 23 trials
- Phase 11 trial
- Phase 31 trial
- Status
- Active, not recruiting7 trials
- Recruiting6 trials
- Completed2 trials
- Lead sponsor
- GlaxoSmithKline14 trials
- Tesaro, Inc.1 trial
Running trials
Recruiting
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
NCT07602777· Phase 1/2· GlaxoSmithKline· Source
Contact: Benjamin Verret (principal investigator)
Recruiting
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
NCT07332455· Phase 1/2· GlaxoSmithKline· Source
Contact: Yohann Loriot (principal investigator)
Recruiting
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
NCT07213609· Phase 1/2· GlaxoSmithKline· Source
Contact: Antoine Hollebecque (principal investigator)
Recruiting
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
NCT07099898· Phase 3· GlaxoSmithKline· Source
Contact: Pernelle Lavaud (principal investigator)
Recruiting
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
NCT06990880· Phase 1/2· GlaxoSmithKline· Source
Contact: Yohann Loriot (principal investigator)
Recruiting
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
NCT06885034· Phase 1/2· GlaxoSmithKline· Source
Contact: Michel Ducreux (principal investigator)
Active, not recruiting
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
NCT06062420· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
NCT07150104· Phase 1/2· GlaxoSmithKline· Source
Active, not recruiting
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
NCT07150091· Phase 1/2· GlaxoSmithKline· Source
Active, not recruiting
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
NCT07217184· Phase 1/2· GlaxoSmithKline· Source
Active, not recruiting
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
NCT07084896· Phase 1/2· GlaxoSmithKline· Source
Active, not recruiting
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
NCT07217119· Phase 1/2· GlaxoSmithKline· Source
Active, not recruiting
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284· Phase 1· Tesaro, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error